Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.
2.

Prostatic marker-negative amphicrine carcinoma of the prostate.

Papadimitriou JC, Weihing RR, Choi C, Drachenberg CB.

Ultrastruct Pathol. 1994 May-Jun;18(3):357-63.

PMID:
7520642
3.

Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.

Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM.

Arch Pathol Lab Med. 1988 Nov;112(11):1100-5.

PMID:
2460064
4.

Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.

Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Duc A.

J Urol. 1996 Apr;155(4):1340-3.

PMID:
8632569
5.

Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.

Yashi M, Terauchi F, Nukui A, Ochi M, Yuzawa M, Hara Y, Morita T.

Urol Oncol. 2006 Jul-Aug;24(4):313-7.

PMID:
16818183
6.

Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.

Cussenot O, Villette JM, Cochand-Priollet B, Berthon P.

Prostate Suppl. 1998;8:43-51. Review.

PMID:
9690663
7.

Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.

Jiborn T, Abrahamson M, Gadaleanu V, Lundwall A, Bjartell A.

BJU Int. 2006 Jul;98(1):189-96.

8.

Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.

Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE.

Cancer. 1993 Jun 15;71(12):3952-65.

9.

Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.

Wang W, Epstein JI.

Am J Surg Pathol. 2008 Jan;32(1):65-71.

PMID:
18162772
10.

A case of synchronous double primary lung cancer with neuroendocrine features.

Niho S, Yokose T, Nagai K, Nishiwaki Y, Kodama T, Mukai K.

Jpn J Clin Oncol. 1999 Apr;29(4):219-25.

PMID:
10340047
11.
12.

Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.

Kimura N, Hoshi S, Takahashi M, Takeha S, Shizawa S, Nagura H.

J Urol. 1997 Feb;157(2):565-8.

PMID:
8996358
13.

Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.

Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L.

J Urol. 2002 Sep;168(3):1204-11.

PMID:
12187268
15.

A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ.

Cancer Res. 2001 Mar 1;61(5):2239-49.

16.

Divergent neuroendocrine differentiation in prostatic carcinoma.

di Sant' Agnese PA.

Semin Diagn Pathol. 2000 May;17(2):149-61. Review.

PMID:
10839615
17.

Neuroendocrine differentiation in prostatic carcinoma.

Abrahamsson PA.

Prostate. 1999 May;39(2):135-48. Review.

PMID:
10221570
18.

Prostatic ductal adenocarcinoma showing Bcl-2 expression.

Tulunay O, Orhan D, Baltaci S, Gögüş C, Müftüoglu YZ.

Int J Urol. 2004 Sep;11(9):805-8.

19.

[Prostatic adenocarcinoma with neuroendocrine differentiation of the small cell type].

Rimoldi DA, Antonio Costa J, Roveto S, Rivero O.

Medicina (B Aires). 2001;61(3):322-4. Spanish.

PMID:
11474882
20.

[Serum chromogranin A in prostate cancer].

Akakura K.

Nihon Rinsho. 2002 Dec;60 Suppl 11:160-4. Review. Japanese. No abstract available.

PMID:
12599564

Supplemental Content

Support Center